Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Kimball

Showing results (321-330 of 373) with videos related to

Pageof 38
Sort By:
Journal of the American Academy of Dermatology|January 30, 2013
OBSERVE-5 interim analysis: an observational postmarketing safety registry of etanercept for the treatment of psoriasisAlexa B Kimball, David Pariser, Paul S Yamauchi, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|April 21, 2022
Unmet clinical needs and burden of disease in hidradenitis suppurativa: real-world experience from EU5 and USJ R Ingram, V Bettoli, J I Espy, et al.
The British Journal of Dermatology|May 10, 2018
Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trialsA Blauvelt, K Reich, K A Papp, et al.
Experimental Dermatology|May 31, 2022
IL-17A is a pertinent therapeutic target for moderate-to-severe hidradenitis suppurativa: Combined results from a pre-clinical and phase II proof-of-concept studyAlexa B Kimball, Christian Loesche, Errol P Prens, et al.
The British Journal of Dermatology|May 11, 2018
Correlation of psoriasis activity with socioeconomic status: cross-sectional analysis of patients enrolled in the Psoriasis Longitudinal Assessment and Registry (PSOLAR)A B Kimball, M Augustin, K B Gordon, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 20, 2022
Impact of childhood atopic dermatitis on life decisions for caregivers and familiesK Capozza, A Schwartz, J E Lang, et al.
Dermatology (Basel, Switzerland)|November 5, 2024
Treatment Satisfaction in Patients with Hidradenitis Suppurativa: A Real-World Survey from the EU5 and USAJohn R Ingram, Vincenzo Bettoli, Jasmine I Espy, et al.
Journal of the American Academy of Dermatology|October 23, 2023
Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled studyJoslyn S Kirby, Martin M Okun, Afsaneh Alavi, et al.
Journal of the American Academy of Dermatology|October 8, 2011
Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trialsKenneth B Gordon, Kim A Papp, Richard G Langley, et al.
Drug Safety|June 11, 2016
Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and PsoriasisMegan E B Clowse, Steven R Feldman, John D Isaacs, et al.
Pageof 38

Showing results (321-330 of 373) with videos related to

Sort By:
Pageof 38
Journal of the American Academy of Dermatology|January 30, 2013
OBSERVE-5 interim analysis: an observational postmarketing safety registry of etanercept for the treatment of psoriasisAlexa B Kimball, David Pariser, Paul S Yamauchi, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|April 21, 2022
Unmet clinical needs and burden of disease in hidradenitis suppurativa: real-world experience from EU5 and USJ R Ingram, V Bettoli, J I Espy, et al.
The British Journal of Dermatology|May 10, 2018
Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trialsA Blauvelt, K Reich, K A Papp, et al.
Experimental Dermatology|May 31, 2022
IL-17A is a pertinent therapeutic target for moderate-to-severe hidradenitis suppurativa: Combined results from a pre-clinical and phase II proof-of-concept studyAlexa B Kimball, Christian Loesche, Errol P Prens, et al.
The British Journal of Dermatology|May 11, 2018
Correlation of psoriasis activity with socioeconomic status: cross-sectional analysis of patients enrolled in the Psoriasis Longitudinal Assessment and Registry (PSOLAR)A B Kimball, M Augustin, K B Gordon, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 20, 2022
Impact of childhood atopic dermatitis on life decisions for caregivers and familiesK Capozza, A Schwartz, J E Lang, et al.
Dermatology (Basel, Switzerland)|November 5, 2024
Treatment Satisfaction in Patients with Hidradenitis Suppurativa: A Real-World Survey from the EU5 and USAJohn R Ingram, Vincenzo Bettoli, Jasmine I Espy, et al.
Journal of the American Academy of Dermatology|October 23, 2023
Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled studyJoslyn S Kirby, Martin M Okun, Afsaneh Alavi, et al.
Journal of the American Academy of Dermatology|October 8, 2011
Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trialsKenneth B Gordon, Kim A Papp, Richard G Langley, et al.
Drug Safety|June 11, 2016
Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and PsoriasisMegan E B Clowse, Steven R Feldman, John D Isaacs, et al.
Pageof 38